05.05.2010 • News

Merck Profit Beats, but 2010 Forecast Cautious

Merck & Co, which recently acquired U.S. rival Schering-Plough, reported better-than-expected first-quarter earnings, but its 2010 profit forecast barely encompassed Wall Street expectations.

Merck earned $299 million, or 9 cents per share, with results hurt by a number of special charges. That compared with $1.43 billion, or 67 cents per share in the year-earlier period.

Excluding special items, Merck earned 83 cents per share. Analysts on average expected 75 cents per share, according to Thomson Reuters I/B/E/S. The company expects 2010 earnings of $3.27 to $3.41 per share, excluding special items. Analysts were expecting $3.41 per share.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Top-Feature

most read